Allurion Technologies Inc (ALUR)

May 29, 2025, 4:05 PM EDT - 8 days ago

Allurion to Present at Jefferies Global Healthcare Conference

May 27, 2025, 4:05 PM EDT - 10 days ago

Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program

May 14, 2025, 2:44 PM EDT - 23 days ago

Allurion Technologies Inc. (ALUR) Q1 2025 Earnings Call Transcript

May 14, 2025, 8:00 AM EDT - 23 days ago

Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 24 days ago

Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss

May 5, 2025, 4:05 PM EDT - 4 weeks ago

Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

Apr 3, 2025, 4:30 PM EDT - 2 months ago

Allurion Announces Postponement of Special Meeting of Stockholders

Mar 26, 2025, 10:44 AM EDT - 2 months ago

Allurion Technologies Inc. (ALUR) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 8:00 AM EDT - 2 months ago

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 20, 2025, 4:05 PM EDT - 2 months ago

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

Mar 12, 2025, 4:05 PM EDT - 3 months ago

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

Mar 4, 2025, 4:05 PM EST - 3 months ago

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

Feb 25, 2025, 4:05 PM EST - 3 months ago

Allurion to Participate in Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 3 months ago

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Feb 19, 2025, 9:03 AM EST - 3 months ago

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Feb 18, 2025, 8:30 AM EST - 3 months ago

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

Feb 13, 2025, 8:30 AM EST - 4 months ago

Allurion Relaunches in France

Jan 24, 2025, 1:25 PM EST - 4 months ago

Allurion Technologies Shares Are Up Today: What's Going On?

Jan 24, 2025, 11:50 AM EST - 4 months ago

Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs

Jan 24, 2025, 9:30 AM EST - 4 months ago

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

Jan 23, 2025, 3:48 PM EST - 4 months ago

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

Jan 21, 2025, 8:30 AM EST - 4 months ago

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

Jan 14, 2025, 9:18 AM EST - 5 months ago

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

Jan 8, 2025, 8:00 AM EST - 5 months ago

Allurion Announces Positive Topline Results From AUDACITY Trial

Dec 24, 2024, 7:00 AM EST - 5 months ago

Allurion Technologies, Inc. Announces Reverse Stock Split

Dec 2, 2024, 8:00 AM EST - 6 months ago

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

Nov 25, 2024, 8:00 AM EST - 6 months ago

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

Nov 13, 2024, 12:43 PM EST - 7 months ago

Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 8:00 AM EST - 7 months ago

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 8:10 AM EST - 7 months ago

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society's Annual Conference

Oct 30, 2024, 8:30 AM EDT - 7 months ago

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Oct 23, 2024, 8:00 AM EDT - 8 months ago

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Oct 9, 2024, 1:46 PM EDT - 8 months ago

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks

GEVO KULR LUCD

Oct 9, 2024, 8:00 AM EDT - 8 months ago

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

Oct 1, 2024, 8:04 AM EDT - 8 months ago

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Sep 5, 2024, 5:30 PM EDT - 9 months ago

Allurion Receives Continued Listing Standards Notice from NYSE

Sep 5, 2024, 8:00 AM EDT - 9 months ago

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Sep 3, 2024, 8:00 AM EDT - 9 months ago

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

Aug 28, 2024, 8:28 AM EDT - 10 months ago

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Aug 13, 2024, 10:18 AM EDT - 10 months ago

Allurion Technologies Inc. (ALUR) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 8:00 AM EDT - 10 months ago

Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 16, 2024, 4:05 PM EDT - 11 months ago

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

Jun 28, 2024, 9:06 AM EDT - 1 year ago

Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement

Jun 26, 2024, 8:36 AM EDT - 1 year ago

Allurion Announces Launch of Offering of Common Stock and Warrants

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

Jun 11, 2024, 8:00 AM EDT - 1 year ago

Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery

Jun 5, 2024, 8:00 AM EDT - 1 year ago

Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

May 30, 2024, 8:00 AM EDT - 1 year ago

Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

May 29, 2024, 4:05 PM EDT - 1 year ago

Allurion to Participate in Two Upcoming Investor Conferences in June 2024

May 15, 2024, 8:00 AM EDT - 1 year ago

Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss